Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HuMax-CD4 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| HuMax-CD4 | DRUG | HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks. |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
HuMax-CD4 is an investigational drug being studied for the treatment of cutaneous T-cell lymphoma, a type of cancer that affects the skin. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
HuMax-CD4 is being developed by Genmab A/S, a biopharmaceutical company listed on the NASDAQ under the ticker symbol GMAB. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with cutaneous T-cell lymphoma.
HuMax-CD4 is in Phase 2 clinical development. Two Phase 2 trials have been completed, both focusing on cutaneous T-cell lymphoma. The drug is still investigational and has not received regulatory approval for any indication.
HuMax-CD4 has been studied in two completed Phase 2 clinical trials: NCT00071071, which enrolled 25 patients with early-stage cutaneous T-cell lymphoma, and NCT00071084, which enrolled 22 patients with advanced-stage disease. Both trials were uncontrolled and non-randomized.
HuMax-CD4 targets the CD4 receptor, which is expressed on certain immune cells. By binding to CD4, the drug is designed to modulate the immune response in cutaneous T-cell lymphoma. However, the exact mechanism of action has not been fully detailed in available information.